Kenyon represented client Watson Pharmaceuticals, Inc. before the Court of Appeals for the Federal Circuit in a patent infringement litigation brought by ALZA Corporation and McNeil-PPC over generic versions of Concerta® developed by Watson’s subsidiaries, Andrx Corporation and Andrx Pharmaceuticals LLC. Kenyon represented Watson in the district court as well as on appeal. After a full trial in March 2009, Judge Joseph Farnan, Jr. of the US District Court for the District of Delaware ruled that the proposed generic versions of Concerta®, which treats Attention-Deficit/Hyperactivity Disorder (“ADHD”), would not infringe US Patent No. 6,919,373 (the '373 Patent) and that the '373 Patent is invalid. On April 26, 2010, the Court of Appeals for the Federal Circuit affirmed Judge Farnan’s ruling by concluding that the asserted claims of the ’373 patent are invalid for lack of enablement. Given the affirmance on grounds of invalidity, the Federal Circuit did not address Judge Farnan’s alternative finding of non-infringement of the asserted claims. Case number 2009- 1350 (2010).